What Is a High-Risk Pregnancy? How Should It Be Monitored?

1) Enhanced prenatal visits

• Visit cadence: typically every 2–4 weeks initially, then weekly or biweekly in the third trimester depending on risk.
• Vitals & screening: blood pressure, weight gain, urinalysis (protein/glucose), edema, mood screening, vaccination review (influenza, Tdap; others as indicated).
• Medication review: optimize chronic disease therapy (e.g., switch ACE inhibitors before conception/pregnancy; adjust anti-epileptics; insulin titration).

2) Targeted laboratory testing

• Early pregnancy: blood type/Rh and antibody screen, CBC, ferritin, thyroid function if indicated, A1C for diabetes risk, infectious disease screen (HIV, hepatitis B, syphilis), rubella/varicella immunity.
• 24–28 weeks: oral glucose tolerance test for gestational diabetes (earlier if high risk).
• Ongoing: renal/liver function tests for hypertensive disorders; urine protein/creatinine ratio; thrombophilia work-up when clinically indicated.

3) Ultrasound and fetal assessment

• Dating scan (≈11–13+6 weeks) and anatomy scan (≈18–22 weeks).
• Serial growth scans every 3–4 weeks if risk of FGR or macrosomia.
• Cervical length surveillance (transvaginal ultrasound) for prior preterm birth or uterine anomalies; consider progesterone therapy or cerclage per history.
• Fetal surveillance from 32–34 weeks (earlier if needed):
  • Non-stress test (NST) and biophysical profile (BPP) weekly or biweekly.
  • Umbilical/middle cerebral artery Dopplers for growth restriction or preeclampsia.
• Fetal echocardiography for diabetes, certain medications, IVF, or abnormal anatomy screen.

4) Condition-specific management (examples)

• Preeclampsia risk reduction: low-dose aspirin (75–150 mg nightly) from 12–16 weeks until 36 weeks for patients with high or multiple moderate risk factors (per major guidelines).
• Gestational diabetes: nutrition therapy, glucose monitoring, exercise, insulin or oral agents when needed; third-trimester growth scans and timing of delivery based on control.
• Chronic hypertension: safe antihypertensives (e.g., labetalol, nifedipine, methyldopa); home BP logs; preeclampsia labs and fetal testing.
• Multiple pregnancy: increased ultrasound frequency for growth and twin-twin transfusion (monochorionic), iron/ferritin support, individualized delivery planning.
• Placenta previa/accreta: pelvic rest as advised; planned cesarean (and accreta team readiness) at an appropriate gestation.
• Autoimmune disease (e.g., SLE, antiphospholipid): disease quiescence before conception; low-dose aspirin ± heparin when indicated; close renal and fetal monitoring.

5) Nutrition, weight, and lifestyle

• Balanced diet with adequate protein, calcium, iron and folate; treat anemia early.
• Weight gain targets individualized by pre-pregnancy BMI.
• Physical activity (unless contraindicated): moderate exercise, pelvic floor training.
• Smoking, alcohol, and substance cessation with structured support.
• Sleep & mental health: screen for depression/anxiety; refer to perinatal psychology when appropriate.

6) Birth planning and timing

• Mode and timing depend on maternal condition, fetal growth and testing, and obstetric history:
  • Well-controlled high-risk conditions may allow term delivery.
  • Preeclampsia with severe features, poorly controlled diabetes/hypertension, FGR with abnormal Dopplers, or ruptured membranes often require earlier delivery.
  • C-section for placenta previa, some malpresentations, prior complicated uterine surgery, or emergent fetal/maternal indications.
• Place of birth: deliver in a facility with NICU and on-site specialists if the risk profile warrants (standard at MedicalPoint Hospital).

7) Postpartum follow-up (the “4th trimester”)

• Early review (7–10 days) for hypertension, diabetes medication adjustments, wound care, mood screening.
• 6–12 weeks: oral glucose tolerance test after gestational diabetes; long-term cardiometabolic prevention for patients with preeclampsia or GDM; lactation support; contraception counseling tailored to medical conditions.